Credit Suisse’s DICE Therapeutics DICE Stock Holding History
Bought
Maintained
Sold
Credit Suisse's DICE Position: Q3 2023 in Review
Credit Suisse sold out of DICE Therapeutics (DICE) in Q3 2023, closing a stake of 69,258 shares — an estimated $3.22M sold.
Credit Suisse first reported a position in DICE in Q2 2022 and held it in 5 quarters. The position peaked at $3.22M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.
- Credit Suisse reported no remaining DICE Therapeutics position as of Q3 2023 after selling out during the quarter.
- Credit Suisse sold 69,258 DICE Therapeutics shares in Q3 2023, an estimated $3.22M.
- Credit Suisse first reported a position in DICE Therapeutics in Q2 2022 and held it in 5 quarters.
- Credit Suisse's DICE Therapeutics position peaked at $3.22M in Q2 2023.
- 0 funds tracked by Wall St. Rank held DICE Therapeutics as of Q3 2023.
Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.